ArticleEJHaem2025
Validation of an Adapted NGS-Based Clonality Assay for MRD Monitoring in B-ALL Using Archived and Follow-Up Samples.
Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Measurable residual disease (MRD) monitoring is a critical component of risk stratification and therapeutic decision-making in B-cell acute lymphoblastic leukemia (B-ALL). Multiparameter flow cytometry (MFC) is widely used, but its sensitivity is limited to 10 Methods: In this retrospective study, 32 B-ALL patients were analyzed. Diagnostic clonotypes were identified from archival stained bone marrow aspirate smears in all cases, and FFPE bone marrow tissue in five. Longitudinal MRD monitoring was performed on bone marrow aspirates collected in EDTA. Serial dilution experiments (10 Results: Baseline clonotypes were detected in 29/32 patients (90.6%). The assay demonstrated a limit of detection of 10 Conclusion: This adapted NGS assay offers a sensitive, reproducible, and sample-flexible MRD monitoring tool for B-ALL, with potential for broader clinical application.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.